A Phase 3 interventional study of Cariprazine and Placebo in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 85 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.
Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 4th largest by enrollment, is one of 4 that started in 2012, is one of 31 in phase 3, and was the 24th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,022 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 442 across the 53 interventional studies. Of the 50 that completed or were terminated, 37 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
1 of the studies in Depressive Disorder, Major by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07276997AbbVieA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Depressive Disorder, Major by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Antidepressant therapy (ADT) as prescribed by the investigator plus single-blind placebo for 8 weeks.
Drug: Placebo · Drug: Antidepressant Therapy (ADT)
Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to dose-matched placebo, once per day, oral administration plus ADT for 8 weeks (up to Week 16).
Drug: Placebo · Drug: Antidepressant Therapy (ADT)
Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to cariprazine, 1.5 to 4.5 milligrams (mg) per day, oral administration plus ADT for 8 weeks (up to Week 16).
Drug: Cariprazine · Drug: Antidepressant Therapy (ADT)
Following the 8 week ADT plus single blind placebo lead-in period, participants who were ADT responders continued treatment with ADT plus placebo for an additional 8 weeks.
Drug: Placebo · Drug: Antidepressant Therapy (ADT)
Cariprazine capsules 1.5 to 4.5 mg/day
Dose-matched placebo capsule once per day
ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline in the Double-Blind Period
The MADRS is a clinician-rated scale to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating and lack of interest. Each item is scored on a 7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity for a total possible score of 0 to 60.
Time frame: Baseline (Week 8)
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) in the Double-Blind Period
The MADRS is a clinician-rated scale to assess depressive symptomatology during the past week. Participants are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating and lack of interest. Each item is scored on a 7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity for a total possible score of 0 to 60. A negative change from Baseline indicates improvement. Mixed-effects model for repeated measures (MMRM) with treatment group, study center, visit, and treatment group-by-visit interaction as fixed effects, and the baseline value and baseline by-visit interaction as the covariates was used for analyses.
Time frame: Baseline (Week 8) to Week 16
Change From Baseline in Sheehan Disability Scale (SDS) Score in the Double-Blind Period
The Sheehan Disability Scale (SDS) is a 3-item patient-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum from 0 (no impairment) to 10 (most severe). The 3 individual scores are summed for a total possible score of 0 (unimpaired) to 30 (highly impaired). A negative change from Baseline indicates improvement. MMRM with treatment group, study center, visit, and treatment group-by-visit interaction as fixed effects, and the baseline value and baseline by-visit interaction as the covariates was used for analyses.
Time frame: Baseline (Week 8) to Week 16
| Milestone | Placebo + ADT Lead-in | Placebo + ADT (Double-Blind) | Cariprazine + ADT (Double-Blind) | Placebo + ADT (Continued Treatment) |
|---|---|---|---|---|
| Started | 1022 | 0 | 0 | 0 |
| Completed | 807 | 0 | 0 | 0 |
| Not completed | 215 | 0 | 0 | 0 |
| Withdrew: Adverse event | 41 | 0 | 0 | 0 |
| Withdrew: Insufficient therapeutic response | 6 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 74 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent | 49 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 34 | 0 | 0 | 0 |
| Withdrew: Site terminated by sponsor | 1 | 0 | 0 | 0 |
| Withdrew: Other reason not specified | 10 | 0 | 0 | 0 |
| Milestone | Placebo + ADT Lead-in | Placebo + ADT (Double-Blind) | Cariprazine + ADT (Double-Blind) | Placebo + ADT (Continued Treatment) |
|---|---|---|---|---|
| Started | 0 | 261 | 269 | 270 |
| Double-blind safety population | 0 | 258 | 269 | 0 |
| Completed | 0 | 222 | 213 | 222 |
| Not completed | 0 | 39 | 56 | 48 |
| Withdrew: Study or site terminated by sponsor | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 3 | 23 | 2 |
| Withdrew: Protocol violation | 0 | 14 | 12 | 19 |
| Withdrew: Withdrawal of consent | 0 | 11 | 11 | 13 |
| Withdrew: Lost to follow-up | 0 | 7 | 10 | 10 |
| Withdrew: Other reason not specified | 0 | 1 | 0 | 3 |
| Withdrew: Did not ingest double-blind treatment | 0 | 3 | 0 | 0 |
The MADRS is a clinician-rated scale to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating and lack of interest. Each item is scored on a 7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity for a total possible score of 0 to 60.
| score on a scale | Placebo + ADT (Double-Blind) | Cariprazine + ADT (Double-Blind) |
|---|---|---|
| Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline in the Double-Blind Period | 25.2 ± 6.1 | 25.4 ± 5.5 |
The MADRS is a clinician-rated scale to assess depressive symptomatology during the past week. Participants are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating and lack of interest. Each item is scored on a 7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity for a total possible score of 0 to 60. A negative change from Baseline indicates improvement. Mixed-effects model for repeated measures (MMRM) with treatment group, study center, visit, and treatment group-by-visit interaction as fixed effects, and the baseline value and baseline by-visit interaction as the covariates was used for analyses.
| score on a scale | Placebo + ADT (Double-Blind) | Cariprazine + ADT (Double-Blind) |
|---|---|---|
| Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) in the Double-Blind Period | -7.5 ± 0.5 | -7.7 ± 0.5 |
The Sheehan Disability Scale (SDS) is a 3-item patient-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum from 0 (no impairment) to 10 (most severe). The 3 individual scores are summed for a total possible score of 0 (unimpaired) to 30 (highly impaired). A negative change from Baseline indicates improvement. MMRM with treatment group, study center, visit, and treatment group-by-visit interaction as fixed effects, and the baseline value and baseline by-visit interaction as the covariates was used for analyses.
| score on a scale | Placebo + ADT (Double-Blind) | Cariprazine + ADT (Double-Blind) |
|---|---|---|
| Change From Baseline in Sheehan Disability Scale (SDS) Score in the Double-Blind Period | -3.1 ± 0.5 | -3.7 ± 0.5 |
Collected over First dose of study drug up to 30 days past last dose of study drug (Up to 12 Weeks for the ADT Lead-In arm) and up to an additional 12 weeks for the Double-Blind and Continued Treatment arms. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + ADT Lead-in | 0/1,022 (0%) | 9/1,022 (0.9%) | 261/1,022 (25.5%) |
| Placebo + ADT (Double-Blind) | 0/258 (0%) | 3/258 (1.2%) | 50/258 (19.4%) |
| Cariprazine + ADT (Double-Blind) | 0/269 (0%) | 1/269 (0.4%) | 101/269 (37.5%) |
| Placebo + ADT (Continued Treatment) | 0/270 (0%) | 1/270 (0.4%) | 14/270 (5.2%) |
| Event | Placebo + ADT Lead-in | Placebo + ADT (Double-Blind) | Cariprazine + ADT (Double-Blind) | Placebo + ADT (Continued Treatment) |
|---|---|---|---|---|
| MigraineNervous system disorders | 0/1022 | 1/258 | 0/269 | 0/270 |
| SeizureNervous system disorders | 0/1022 | 1/258 | 0/269 | 0/270 |
| Pancreatitis acuteGastrointestinal disorders | 0/1022 | 1/258 | 0/269 | 0/270 |
| CholelithiasisHepatobiliary disorders | 0/1022 | 1/258 | 0/269 | 0/270 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/1022 | 1/258 | 0/269 | 0/270 |
| Suicidal ideationPsychiatric disorders | 1/1022 | 0/258 | 1/269 | 0/270 |
| DepressionPsychiatric disorders | 0/1022 | 0/258 | 1/269 | 0/270 |
| Confusional statePsychiatric disorders | 0/1022 | 0/258 | 0/269 | 1/270 |
| GastroenteritisInfections and infestations | 1/1022 | 0/258 | 0/269 | 0/270 |
| PneumoniaInfections and infestations | 1/1022 | 0/258 | 0/269 | 0/270 |
| Event | Placebo + ADT Lead-in | Placebo + ADT (Double-Blind) | Cariprazine + ADT (Double-Blind) | Placebo + ADT (Continued Treatment) |
|---|---|---|---|---|
| AkathisiaNervous system disorders | 0/1022 | 8/258 | 46/269 | 0/270 |
| NauseaGastrointestinal disorders | 91/1022 | 10/258 | 17/269 | 0/270 |
| HeadacheNervous system disorders | 91/1022 | 15/258 | 22/269 | 0/270 |
| RestlessnessPsychiatric disorders | 0/1022 | 5/258 | 23/269 | 0/270 |
| InsomniaPsychiatric disorders | 68/1022 | 18/258 | 22/269 | 0/270 |
| DiarrhoeaGastrointestinal disorders | 57/1022 | 0/258 | 0/269 | 0/270 |
| SomnolenceNervous system disorders | 0/1022 | 3/258 | 14/269 | 0/270 |
| NasopharyngitisInfections and infestations | 0/1022 | 0/258 | 0/269 | 14/270 |
Pre-Randomization Safety Population included all patients in the screened population who took at least 1 dose of prospective open-label ADT plus single-blind placebo during the prospective ADT lead-in period of the study.
| Age, Continuous(years) | Placebo + ADT Lead-in |
|---|---|
| Mean | 44.1 ± 12.0 |
| Sex: Female, Male(Participants) | Placebo + ADT Lead-in |
|---|---|
| Female | 673 |
| Male | 349 |
| Race/Ethnicity, Customized(Participants) | Placebo + ADT Lead-in |
|---|---|
| Race — White | 741 |
| Race — Black or African American | 250 |
| Race — Asian | 18 |
| Race — American Indian or Alaska Native | 8 |
| Race — Native Hawaiian or Other Pacific Islander | 3 |
| Race — Other | 2 |
| Race/Ethnicity, Customized(Participants) | Placebo + ADT Lead-in |
|---|---|
| Ethnicity — Hispanic or Latino | 234 |
| Ethnicity — Not Hispanic or Latino | 788 |
Ran from Nov 2012 to primary completion in Jun 2016, 43 months.
Results were first posted in Aug 2019, 3 years 2 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 43 months is above that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine